- Home
- HOOK vs TURN Comparison
HOOK vs TURN Comparison
Compare HOOK & TURN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOOK
- TURN
- Stock Information
- Founded
- HOOK 2011
- TURN 1981
- Country
- HOOK United States
- TURN United States
- Employees
- HOOK N/A
- TURN N/A
- Industry
- HOOK Biotechnology: Pharmaceutical Preparations
- TURN Finance/Investors Services
- Sector
- HOOK Health Care
- TURN Finance
- Exchange
- HOOK Nasdaq
- TURN Nasdaq
- Market Cap
- HOOK 9.3M
- TURN 39.9M
- IPO Year
- HOOK 2019
- TURN N/A
- Fundamental
- Price
- HOOK $1.25
- TURN $3.98
- Analyst Decision
- HOOK Buy
- TURN
- Analyst Count
- HOOK 4
- TURN 0
- Target Price
- HOOK $10.67
- TURN N/A
- AVG Volume (30 Days)
- HOOK 60.9K
- TURN 20.2K
- Earning Date
- HOOK 08-07-2025
- TURN 01-01-0001
- Dividend Yield
- HOOK N/A
- TURN N/A
- EPS Growth
- HOOK N/A
- TURN N/A
- EPS
- HOOK N/A
- TURN N/A
- Revenue
- HOOK $9,351,000.00
- TURN $194,813.00
- Revenue This Year
- HOOK N/A
- TURN N/A
- Revenue Next Year
- HOOK N/A
- TURN N/A
- P/E Ratio
- HOOK N/A
- TURN N/A
- Revenue Growth
- HOOK N/A
- TURN 254.25
- 52 Week Low
- HOOK $0.72
- TURN $3.12
- 52 Week High
- HOOK $6.77
- TURN $4.25
- Technical
- Relative Strength Index (RSI)
- HOOK 38.94
- TURN 55.53
- Support Level
- HOOK $1.23
- TURN $3.93
- Resistance Level
- HOOK $1.30
- TURN $4.00
- Average True Range (ATR)
- HOOK 0.06
- TURN 0.08
- MACD
- HOOK -0.03
- TURN 0.00
- Stochastic Oscillator
- HOOK 5.97
- TURN 94.89
About HOOK HOOKIPA Pharma Inc.
HOOKIPA Pharma Inc is a clinical-stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. Its oncology portfolio targets oncoviral cancer antigens and next-generation antigens and includes two primary programs in development: eseba-vec (formerly HB-200) and HB-700. Eseba-vec is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers. It also develops infectious disease therapies in partnership with other companies. Its Hepatitis B (HBV) program, HB-400, and Human Immunodeficiency Virus (HIV) program, HB-500, are being developed in partnership with Gilead.
About TURN 180 Degree Capital Corp.
180 Degree Capital Corp is active in the financial services domain. It is a non-diversified closed-end management investment company whose objective is to achieve long-term capital appreciation by making venture capital investments. It focuses its investments on companies commercializing and integrating products enabled by disruptive technologies mainly in the life sciences, precision medicine, and health industries.